For independent biotech analysts

Start with the evidence.
Keep your research connected.

For analysts following 5–10 U.S.-listed biotech companies. Explore the Free research workflow first. Starter is the planned monthly option for a focused coverage list and eligible monitoring and export features.

LIVE CHECKOUT NOT CURRENTLY AVAILABLE Free on-demand research is available. Starter monitoring requires paid access after approval. Request Starter updates
Starter checkout is not yet available · Free access is available

Monthly billing only. Annual plans are not offered until annual checkout prices are configured and verified.

Paid activation is currently unavailable. You can explore Free access or request a Starter launch update without adding a payment card. Analyst is not available for purchase.

Review the Evidence Quality page for source coverage, freshness, conflicts, and missing evidence. These measures describe research provenance, not investment attractiveness or future performance.

Want a checkout update? Join the Starter launch list. This requests one launch update; it does not grant beta or paid access.

Pricing tiers

AVAILABLE NOW · NO CARD REQUIRED

Free

Try a company you already know. Review what the returned sources support and which questions remain open.
$0
One researcher · No paid subscription
Start free research
  • Up to 5 production analysis requests per day
  • Company and clinical-trial source evidence
  • Saved briefs you can reopen
  • 3 private research notes with up to 3 linked sources
  • Visible source gaps and limitations
Free does not include: ongoing source-change monitoring, PDF or CSV exports, or paid-plan access. Source availability and query coverage can vary.
Read the historical ALNY sample first
FOR A FOCUSED COVERAGE LIST
AVAILABLE AFTER CHECKOUT APPROVAL

Starter

Source-linked research continuity. A planned monthly workspace for one analyst following a focused list of companies, clinical trials, and original evidence.
$29 / mo
Monthly billing
Create free account Join the $29 Starter launch list
  • Coverage list of up to 10 companies
  • Up to 20 pipelines or clinical trials
  • Recorded source changes where monitoring is available
  • 30 on-demand evidence reports / month
  • Available change history and original source links
  • 100 active notebook notes and 20 linked source records
  • Field-level review queue and revocable public citations
  • Notebook export in Markdown and JSON
  • PDF and CSV export
  • Single user
Facts-only scope: historical and current source-linked records only. No personalized advice, scores, rankings, recommendations, or future-performance forecasts.
30 analyses / month:
Terms apply to billing and cancellation policy.
Coverage boundary: inspect collection status, source dates, and gaps before relying on a comparison. No real-time or uninterrupted daily monitoring guarantee is offered.
Future plans and team inquiries — not available for purchase
FUTURE AND INQUIRY OPTIONS

Starter is the only planned self-serve paid plan.

Analyst is not for sale. Research Desk and Enterprise are inquiry-led future programs. Their presence below describes boundaries and direction, not currently purchasable functionality.

COMING SOON | NOT FOR SALE

Analyst

Scientific Intelligence Terminal. A future proactive workspace for professional researchers who need continuous scientific change discovery.
$149 / mo
Not available for purchase before required registration is complete
Registration required before Analyst can launch.
  • Coming Soon: Personalized research feed
  • Coming Soon: Clinical, regulatory, and patent timelines
  • Coming Soon: Drug and company landscape mapping
  • Coming Soon: Cross-source evidence synthesis
  • Coming Soon: Daily and weekly scientific briefings
  • Everything currently available in Starter
Maturity: these proactive capabilities are product direction, not currently available functionality. No continuous monitoring or delivery guarantee is offered today.
Registration lock: this plan is not offered for purchase until the applicable investment-advisory education, registration, and launch review are complete.
200 analyses / month:
Terms apply to billing and cancellation policy.
Continuous scientific intelligence: surface source-recorded developments before the user begins a new search.
REQUEST ACCESS
FUTURE VISION | TEAM PROGRAM

Research Desk

For research teams evaluating portfolio monitoring and source-linked workflows with at least three users.
₩740,000 / seat / mo | 3-seat minimum
Request access | no self-serve checkout
Request access
Organization administration remains available by pilot arrangement only. API access requires an explicitly agreed scope.
  • Everything in Analyst, plus:
  • Portfolio Intelligence
  • Advanced Alerts and competitor pipeline comparison
  • CSV export (PILOT ONLY; provisioned scope)
  • API access where explicitly provisioned
  • Priority support
Pilot-only today: organization administration and monthly research review (available by arrangement). No SLA, SSO/SAML, or guaranteed continuous monitoring.
For a 6-week guided evaluation instead, request a Fund Pilot with named companies and written success criteria.
FUTURE VISION | NOT A PUBLIC PLAN

Enterprise

For organizations that want to discuss a future production scope after pilot validation.
Custom
By inquiry only — no public SLA, SSO/SAML, or seat entitlement is offered today
Talk to us
  • Readiness and security review
  • Proposed coverage and data-boundary review
  • Commercial and operational terms confirmed before any commitment

Start with the access available today.

Starter is the planned monthly subscription for independent researchers. Paid activation is not yet available. You can review the workspace, sources, and sample reports before deciding whether the plan fits your work.

Explore analysis and source transparency through the Free plan. No payment card is required for Free access.

Join the $29 Starter launch list

Request an email when Starter checkout becomes available. No payment card is required. We will use this signup to send the launch update you requested.

Capability status

Operational status is shown separately from product positioning: Available, Coming Soon, and Future Vision are never presented as equivalent.

* Standard coverage. Large-cap companies with unusually broad clinical pipelines can take longer while ORION processes the additional source material.

Optional: Starter and future Analyst scope

Starter is the current individual workflow. Analyst remains future direction.

The table preserves the product boundary without presenting Analyst as a service available for purchase today.

Research needStarter · Available after approvalAnalyst · Coming Soon
Starting pointUp to 10 companies and 20 pipelines you choose to trackCross-portfolio signal discovery, no watchlist limit
Primary outputRecorded changes where available, plus source-linked briefs on demandPersonalized feed, landscape mapping, cross-source synthesis
Current availabilityCheckout opens only after approval and validationNot for sale; no monitoring service is implied

Join Analyst product updates

Questions, answered straight

Is this investment advice?

No. ORION is a research tool. It surfaces, structures, and summarizes public clinical and regulatory data so you can form your own view. It does not make trades or give personalized recommendations.

Where does the data come from?

Public clinical-trial records, regulatory records, and company disclosures. Inspect the links and evidence scope in each brief. A retrieved record or source link does not independently validate every generated statement.

What makes ORION different from a database or general AI chatbot?

ORION does not claim to replace a comprehensive commercial database. It is a research workflow that resolves biotech entities, organizes returned evidence into a consistent brief, preserves source links and timestamps, and keeps missing or conflicting facts visible.

What exactly am I paying $29 for?

Starter is planned at $29 per month for one analyst: a coverage list of up to 10 companies and 20 pipelines or trials, 30 on-demand reports per month, saved briefs, eligible exports, and recorded changes where monitoring is available. Collection status, source dates, and missing evidence matter: coverage is not complete or guaranteed in real time. Paid activation remains unavailable while checkout approval is pending.

Is Analyst available now?

No. Analyst is a Coming Soon product direction for proactive scientific intelligence. It is not currently for sale, and ORION does not imply that continuous monitoring is operating for Analyst customers today.

Can I cancel anytime?

Monthly self-serve plans cancel at the end of the current billing cycle. Annual billing is not currently offered. Guided-pilot terms, if any, are confirmed separately in writing.

Do you offer a trial?

The Free plan is the trial - up to 5 production analysis requests a day, no card required, with source-linked research and saved briefs. Free does not include ongoing source-change monitoring or PDF/CSV exports. Creating a Free account does not activate Starter. Source availability can vary and missing inputs remain explicitly unavailable.

Is there a methodology document for compliance review?

Yes — source selection, freshness rules, conflict handling, missing-data behavior, and disclosed limitations are in the Methodology Whitepaper, downloadable as a PDF for institutional due diligence.

What does a Full-Access report actually look like?

See a full worked example — Watchtower monitoring results and an immutable evidence record — on the sample report page. It uses an illustrative demo company and is clearly watermarked as a sample.

This is a research support tool and does not provide individualized investment consulting or asset management.
Investment principal may be lost, and any such loss is borne by the investor.
ORION is not a licensed financial investment business and does not provide regulated investment services.